Effects of cholinesterase inhibitors on a two-component chained schedule performance in rats

Neurotoxicology and Teratology

Volumn 22, Issue 3, 2000, Pages 389-396

  Liu, Wu Fu ^a  

^a CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Brightness discrimination; DRL DRH chained schedule; Heptylphysostigmine; Organophosphate poisoning; Physotigmine; Tacrine

Indexed keywords

CHOLINESTERASE INHIBITOR; HEPTYLPHYSOSTIGMINE; PHYSOSTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ACETYLCHOLINE BRAIN LEVEL; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CHOLINERGIC SYSTEM; COGNITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANIMALS; CHOLINESTERASE INHIBITORS; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; PHYSOSTIGMINE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT SCHEDULE; SERIAL LEARNING; TACRINE; WATER;

EID: 0034612055     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0892-0362(99)00086-0     Document Type: Article

References (50)

1. Aldridge W.N., Reiner E. Enzyme inhibitors as substrates. Interaction of esterases with esters of organophosphorous and carbamic acids Neuberger A., Tatum E.L. Frontiers of Biology. 1972;123-146 North Holland Publishing Company, Amsterdam.
2. Becker R., Giocobini E. Mechanisms of cholineresterase inhibition in senile dementia of the Alzheimer type. Clinical, pharmacological, and therapeutic aspects Drug Dev Rev. 12:1988;163-195.
3. Berry W.K., Davis D.R. The use of carbamates and atropine in the protection of animals against poisoning by 1,2,3-trimethylpropyl methylphosphonofluoridate. Biochem Pharmacol. 19:1970;927-934.
4. Bierer L.M., Harotunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schemeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease. Relative importance of the cholinergic deficit J Neurochem. 64:1995;749-760.
5. Brufani M., Castellano D., Marta M., Olverio A., Pagella P.G., Pavone F., Pomponi M., Rugarli P.L. A long-lasting cholinesterase inhibitor affecting neural and behavioral processes. Pharmacol Biochem Behav. 26:1987;625-629.
6. Canal N., Imbimbo B.P. Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Clin Pharmacol Ther. 60:1996;218-228.
7. Caudra G., Giacobini E. Effects of cholinesterases and clonidine coadministration on rat cortex neurotransmitters in vivo. J Pharmacol Exp Ther. 275:1995;228-236.
8. Caudra G., Summers K., Giacobini E. Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo. J Pharmacol Exp Ther. 270:1984;277-284.
9. Dawson R.M. Reversibility of the inhibition of acetylcholinerterase by tacrine. Neurosci Lett. 118:1990;85-87.
10. Dawson G.R., Bentley G., Draper F., Rycroft W., Iversen S.D., Pagella P.G. The behavioral effects of heptylphysostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents. Pharmacol Biochem Behav. 39:1991;856-871.
11. DeNoble V.J., Denoble K.F., Spencer K.R., Johnson L.C., Cook L., Myers M.J., Scribner R.M. Comparison of DuP 996, with physostigmine, THA and 3,4-DAP on hypoxia-induced amnesia in rats. Pharmacol Biochem Behav. 36:1990;957-961.
12. De Sarno P., Pomponi M., Giacobini E., Tang X.C., Williams E. The effect of heptylphysostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat. Neurochem Res. 14:1989;971-977.
13. Drukarch B., Leysen J.E., Stoof J.C. Further analysis of the neuropharmacological profile of 9-amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease. Life Sci. 42:1988;1011-1017.
14. Elble R., Giacobini E., Becker R., Zec R., Vicari S., Wormack C., Williams E., Higgins C. Treatment of Alzheimer dementia with steady state infusion of physostigmine. Giacobini E., Becker R. Current Research in Alzeheimer Therapy. 1988;Taylor-Francis, New York.
15. Enz A., Amstutz R., Boddeke H., Gmelin G., Malanowski J. Brain selective inhibition of acetylcholinesterase. A novel approach to therapy for Alzheimer's disease Prog Brain Res. 98:1993;431-438.
16. Freeman S.E., Dawson R.M. Tacrine. A pharmacological review Prog Neurobiol. 36:1991;257-277.
17. Galli A., Mori F. Effectiveness of 1,2,3,4-tetrahydro-9-aminoacridine (THA) as a pretreatment drug for protection of mice from acute diisopropylfluorophosphate (DFP) intoxication. Arch Toxicol. 65:1991;330-334.
18. Hagan J.J., Jansen J.H.M., Brockkamp C.L.E. Hemicholinium-3 impairs spatial learning and the deficit is reversed by cholinomimetics. Psychopharmacol. 98:1989;347-356.
19. Harris L.W., Lennox W.J., Talbot B.G., Anderson D.R., Swanson D.R. Toxicity of anticholinesterases. Interactions of pyridostigmine and physostigmine with soman Drug Chem Toxicol. 7:1984;507-526.
20. Harris L.W., Anderson D.R., Pastelak A.M., Bowerxox S.L., Vanderpool B.A., Lennox W.J. Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine. Drug Chem Toxicol. 15:1992;127-143.
21. Hodges J., Riberio A.M., Gary J.A., Marchbanks R.M. Low dose tetrahydroaminoacridine (THA) improves cognitive function but does not affect brain acetylcholine in rats. Pharmacol Biochem Behav. 36:1990;291-298.
22. Hunter A.J., Murray T.K., Jones J.A., Cross A.J., Green A.R. The cholinergic pharmacology of tetrahydoacridine in vivo and in vitro. Brit J Pharmacol. 98:1989;79-86.
23. Iijima S., Greig M.H., Garofaol P., Spangler E.L., Heller B., Brossi A., Ingram D.K. The long-lasting cholinesterase heptylphysostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze. Neurosci Lett. 144:1992;79-82.
24. Kawashima K., Sato A., Yoshizawa M., Fuji T., Fujimoto K., Suzuki T. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn-Schmied Arch Pharmacol. 350:1994;523-528.
25. Kumar V., Becker R.E. Clinical pharmacology of tetrahydroaminoacridine. A possible therapeutic agent for Alzheimer's disease Int J Clin Pharmacol Ther Toxicol. 10:1989;478-485.
26. Lamy P.P. The role of cholinesterase inhibitors in Alzheimer's disease. CNS Drug. 1:1994;146-165.
27. Leadbetter L., Inns R.J., Rylands J.M. Treatment of poisoning by soman. Fundam Appl Toxicol. 5:1985;S225-S231.
28. Lennox W.J., Harris L.W., Talbot B.G., Anderson D.R. Relationship between reversible acetylcholinestrerase inhibition and efficacy against soman lethality. Life Sci. 37:1985;793-798.
29. Litchfield J.T., Wilcoxon E. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 96:1949;99-113.
30. Liu W.F. Cholinolytic antagonism to the disruptive effects of oral low doses of pyridostigmine on simple discrimination performance in rats. Pharmacol Biochem Behav. 40:1991;745-749.
31. Liu W.F. Acute effects of oral low doses of pyridostigmine on simple visual discrimination and unconditioned consummatory acts in rats. Pharmacol Biochem Behav. 41:1992;251-254.
32. Liu W.F. Effects of antimuscarinic antiparkinsonian drugs on brightness discrimination performance in rats. Pharmacol Biochem Behav. 54:1996;425-430.
33. W.F. Liu, J.H. Shih, Behavioral effects of physotigmine as prophylaxis against organophosphate poisoning, Proceedings of the Third National Conference on Science and Technology of National Defense, Oct. 15, 1994, Taiwan, R. O. C., pp. 263-271 (in Chinese with English abstract).
34. Matsuoka N., Maeda N., Ohkubo Y., Yamaguchi I. Differential effects of physostigmine and pilocarpine on the spatial memory deficits produced by two septo-hippocampal deafferentations. Brain Res. 559:1991;233-240.
35. D.M. Maxwell, K.M. Brech, D.D.E. Lenz, Effect of carboxylesterase inhibition on carbamate protection against soman toxicity, Proc Sixth Med Chem Def Biosci Rev (1987) 17-24.
36. Messamore E., Organe N., Giacobini E. Cholinesterase inhibitor effects on extracellular acethylcholine in rat striatum. Neuropharmacol. 32:1993;291-296.
37. Messamore E., Warpman U., Ogane N., Giacobini E. Cholinesterase inhibitor effects on extracellular acetylcholine in rat cortex. Neuropharmacol. 8:1993;745-750.
38. Miller S.A., Blick D.W., Kerenyi S.Z., Murphy M.R. Efficacy of physostigmine as a pretreatment for organophosphate poisoning. Pharmacol Biochem Behav. 44:1993;343-347.
39. Nielsen J.A., Mena E.E., Williams I.H., Nocerini M.R., Liston D. Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol. 173:1989;53-64.
40. Pomponi M., Giacobini E., Brufani M. Present state and future development of the therapy of Alzheimer's disease. Aging. 2:1990;125-153.
41. Reitzmann R.F., Kling A., Melchior C.L., Glasky A.J. Effects of age and strain on working memory in mice as measured by win-shift paradigm. Pharmacol Biochem Behav. 44:1993;805-807.
42. Kr P., Riekkinen J., Sirvio P., Riekkinen The effects of THA on medial septal lesion-iduced memory defects. Pharmacol Biochem Behav. 36:1990;237-241.
43. Rupniak N.M.J., Tye S.J., Brazell C., Heald A., Iversen S.D., Pagella P.G. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates. J Neurol Sci. 107:1992;246-249.
44. Schneider L.S. Clinical pharmacology of aminoacridines in Alzheimer's disease. Neurol. 43:1993;S64-S79.
45. Somani S.M., Dube S.N. In vivo dose response response relationship between physostigmine and cholineraerase activity in RBC and tissues of rats. Life Sci. 44:1989;1907-1915.
46. Unni L.K., Hutt V., Imbimbo B.P., Becker R.E. Kinetics of cholinesterase inhibition by eptastigmine in man. Eur J Clin Pharmacol. 42:1991;83-84.
47. Vivas N.M., Badia A., Marmol F., Dierssen M. Differential effects of physostigmine and 1,2,3,4-tetrahydroacridine on the β-adrenoceptor transduction system. Eur J Pharmacol Mol Pharmacol Sec. 245:1993;9-13.
48. Watkins P.B., Zimmerman H.J., Knapp M.J., Gracon S.I., Lewis K.W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. J Amer Med Assoc. 271:1994;992-998.
49. Weinstock M. The pharmacology of Alzheimer's disease based on the cholinergic hypothesis. An update Neurodegeneration. 4:1995;349-356.
50. Waite J.J., Thal L.J. The behavioral effects of heptylphysostigmine on rats lesioned in the nucleus basalis. Neurosci Res. 21:1995;251-259.